Urologic Cancers Clinical Trials
As a National Cancer Institute-designated comprehensive cancer center, City of Hope’s urology and urologic oncology program is uniquely positioned to provide personalized and comprehensive treatment plans, along with access to groundbreaking clinical trials.
For more than a decade, U.S. News & World Report has named City of Hope one of the top cancer hospitals in America, as well as named a high performing hospital in urology. Our world-class experts offer urology and urologic cancer patients, including those with complicated cases, access to a wide variety of trials, evaluating leading-edge treatments and innovative therapies.
To refer a patient to one of our clinical trials, please call 626-218-1133 or visit CityofHope.org/Clinical-Trials.
Advanced or Metastatic Urothelial Cancer
NCT04223856: Yung Lyou, M.D., Ph.D., is actively recruiting patients for a Phase 3 study on the benefits of a combination therapy to treat patients with untreated locally advanced or metastatic urothelial cancer.
Patient Enrollment Qualifications
- 18 years of age or older
- Histologically documented, unresectable locally advanced or metastatic urothelial carcinoma
- Adequate hematologic and organ function